Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have earned an average recommendation of “Hold” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $62.1667.

SUPN has been the subject of a number of research reports. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday, March 8th. Stifel Nicolaus lifted their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Finally, Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 8,787 shares of the business’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $53.00, for a total value of $465,711.00. Following the sale, the director directly owned 27,277 shares of the company’s stock, valued at approximately $1,445,681. The trade was a 24.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jack A. Khattar sold 35,000 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $50.37, for a total value of $1,762,950.00. Following the completion of the sale, the chief executive officer directly owned 958,100 shares in the company, valued at approximately $48,259,497. This represents a 3.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 120,881 shares of company stock worth $6,139,356 over the last three months. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Hantz Financial Services Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 281 shares during the last quarter. Rockefeller Capital Management L.P. raised its holdings in shares of Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares during the last quarter. Torren Management LLC purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $49,000. USA Financial Formulas bought a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $50,000. Finally, EverSource Wealth Advisors LLC bought a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $51,000.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $50.79 on Friday. Supernus Pharmaceuticals has a one year low of $29.16 and a one year high of $59.68. The stock has a market capitalization of $2.92 billion, a P/E ratio of -74.69, a price-to-earnings-growth ratio of 1.56 and a beta of 0.70. The business’s 50 day simple moving average is $51.00 and its two-hundred day simple moving average is $49.32.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.